Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | -83.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.72 | N/A | -83.21% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced this quarter while reiterating their focus on future growth. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in achieving profitability.
They emphasized their commitment to long-term goals despite current setbacks.
Despite missing on EPS expectations, Tyra Biosciences saw a significant stock increase of nearly 20%. This positive reaction may be attributed to investor optimism about the company's long-term potential, even in light of current losses. The lack of revenue data and guidance may leave some investors cautious, but the stock's rise suggests confidence in future developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021